Mevlyq (Eribulin Mesylate)

Eribulin mesylate binds to the plus ends of microtubules, preventing further polymerisation. This inhibition of microtubule growth blocks the G2‑M phase of the cell cycle, leading to apoptosis of rapidly dividing cancer cells. Its mechanism is distinct from other microtubule‑targeting agents.

The specific dose and infusion schedule of Mevlyq are determined by the prescribing oncologist based on the patient’s clinical condition, prior therapies, and laboratory parameters. The medication is supplied as a sterile intravenous solution that must be prepared and administered according to the prescriber’s orders.

The safety of eribulin mesylate during pregnancy and lactation has not been established. It is contraindicated for use in pregnant women because of potential fetal toxicity, and breastfeeding is not recommended while receiving treatment. Women of child‑bearing potential should use effective contraception.

To request Mevlyq, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and the necessary import documentation.

Compared with other microtubule‑targeting agents such as taxanes, eribulin offers a distinct mechanism of action and has demonstrated overall‑survival benefit in patients who have progressed after anthracycline and taxane therapy. Its safety profile differs, with lower rates of neuropathy but higher incidence of neutropenia, making it a valuable option in later‑line settings.

Mevlyq should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use, and any prepared infusion should be administered promptly according to the label instructions.

Mevlyq is given as an intravenous infusion, typically over a period of several minutes to an hour, depending on the prescribed dose. The infusion is performed in a clinical setting by qualified healthcare professionals, with appropriate monitoring of vital signs and laboratory parameters before, during, and after administration.

The most serious adverse events reported with eribulin include severe neutropenia that can lead to febrile neutropenia, infections, pulmonary toxicity, and rare cases of cardiac dysfunction. Patients should be closely monitored for signs of infection, respiratory distress, and cardiac symptoms, and appropriate supportive care should be provided promptly.

Mevlyq is contraindicated in patients with known hypersensitivity to eribulin or any component of the formulation. It should also be avoided in pregnant women and in individuals with uncontrolled infections or severe hepatic impairment unless the benefits outweigh the risks as assessed by the treating physician.